In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...

Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...

The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...

Delaware's highest court ruled on Thursday that nearly 75,000 patients suing four large drugmakers cannot introduce reports ...

Despite concerns about cancer-causing agents in Ranitidine and an expert panel's recommendation to suspend it, India's drug advisory body has decided to form another committee to investigate. Previous ...

The government may consider a nationwide ban on the widely used antacid ranitidine after an expert committee reportedly submitted a detailed report highlighting its potential cancer risks. According ...

After years of deliberation, India is likely to ban the widely used over-the-counter (OTC) antacid Ranitidine due to cancer-causing concerns, News18 has learnt. The ban has been recommended by an ...

British drugs firm GSK has been accused of burying a report said to prove a link between its medication Zantac and cancer, a new lawsuit has claimed. A pension fund has filed a class action ...

Zantac’s Developer Settles Lawsuits Claiming Cancer Link GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

(Reuters) -The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer ...